

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 January 2008 (10.01.2008)

PCT

(10) International Publication Number
WO 2008/003451 A1

(51) International Patent Classification:

G01N 33/80 (2006.01) *G01N 1/44* (2006.01)
G01N 33/96 (2006.01) *G01N 33/94* (2006.01)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(21) International Application Number:

PCT/EP2007/005849

(22) International Filing Date: 2 July 2007 (02.07.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

06013762.7 3 July 2006 (03.07.2006) EP
06015470.5 25 July 2006 (25.07.2006) EP

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): **SEBO GMBH** [DE/DE]; Oppertsweg 6, 64711 Erbach (DE).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventor; and

(75) Inventor/Applicant (for US only): **SEIDEL, Dietrich** [DE/DE]; Pschorrstrasse 21, 82340 Feldafing (DE).

(74) Agents: **DEY, Michael** et al.; Weickmann & Weickmann, Postfach 860 820, 81635 München (DE).

WO 2008/003451 A1

(54) Title: A METHOD AND DEVICE FOR PROCESSING A BIOLOGICAL FLUID FOR ANALYTE DETERMINATION

(57) Abstract: The present invention refers to a method of processing a biological fluid which comprises cellular components by heat treatment. The method is particularly useful for preparing biological samples for analyte detection. Further, the invention refers to a processed biological fluid comprising substantially quantitatively disintegrated cellular components.

- 1 -

A method and device for processing a biological fluid for analyte determination

5

Specification

The present invention refers to a method and device for processing a biological fluid which comprises cellular components by heat treatment. The method is particularly useful for preparing biological samples for analyte detection. Further, the invention refers to a processed biological fluid comprising substantially quantitatively disintegrated cellular components.

The determination of analytes in samples from biological fluids often requires complicated and tedious pretreatment procedures in order to remove cellular components from the fluid sample. For example, whole blood contains components, namely erythrocytes, leukocytes and thrombocytes. In order to determine analytes in a blood sample, these cellular components often have to be removed by pre-treatment procedures such as centrifugation, filtration, sedimentation and/or homogenized by lysis using chemical reagents or mechanical treatment. These procedures, however, are often difficult to integrate into an automated test format. This holds also for a situation in which the target analytes are present in the cellular components, e.g. immuno-suppressive drugs in erythrocytes. In this case, the cellular components either are isolated or enriched by centrifugation and/or filtration prior to the addition of a lysis reagent or they are denatured by addition of a denaturing agent to the original sample, for example a mixture of $ZnSO_4$ and acetonitrile, or the original sample is treated with temperatures of -20 to -170°C.

30 An object of the present invention was to provide an improved method for processing biological fluids which does not have the disadvantages associated with prior art procedures.

- 2 -

A first aspect of the present invention is a method of processing a biological fluid which comprises cellular components,

wherein the fluid is subjected to a heat treatment under conditions

- 5 (i) to provide substantially quantitative disintegration of said cellular components and
- (ii) not to cause substantial sedimentation, precipitation, denaturation, agglutination and gelation of fluid components.

A further aspect of the present invention is a processed biological fluid comprising substantially quantitatively disintegrated cellular components which is substantially free from sedimentation, precipitation, denaturation, agglutination and gelation products.

Still a further aspect of the present invention is a method of determining an analyte in a biological fluid sample, wherein the biological fluid is processed as described above and the analyte is determined in the processed biological fluid.

Still a further aspect of the present invention is a device for processing a biological fluid, which comprises cellular components comprising:

- (a) a fluid introduction port,
- (b) a fluid processing conduit, which is at least partially heatable,
- (c) a heating element for heating a predetermined part of the fluid processing conduit,
- 25 (d) a fluid transportation element, e.g. a pumping element,
- (e) a control element for controlling the heating of the fluid under conditions
 - (i) to provide substantially quantitative disintegration of said cellular components and
 - (ii) not to cause substantial sedimentation, precipitation, denaturation, agglutination and gelation of fluid components.
- 30 (f) optionally a cleaning element and
- (g) optionally a sample analyzing element.

- 3 -

Surprisingly, the present inventor has found that a complete disintegration of cellular components, preferably cells or cell clusters from higher organisms, more preferably animal cells such as mammalian cells including human cells, and most preferably blood cells such as erythrocytes, leukocytes and/or thrombocytes in biological samples may be achieved by heat treatment under predetermined conditions of time and temperature. By means of this heat treatment, the cellular components contained in a biological fluid are disintegrated without substantial sedimentation, precipitation, denaturation, agglutination and/or gelation of fluid components.

10

The heat treatment may be carried out at a temperature of from 60-90°C, preferably from 60-75°C and more preferably from 65-70°C. The heat treatment is carried out for a time sufficient to achieve a desired disintegration at the chosen treatment temperature. Preferably, the heat treatment is carried out for a time of 5 sec to 1 min, more preferably from 10 sec to 40 sec. Especially preferred is a temperature of 70°C for 30-40, e.g. 35 sec. The heat treatment may be carried out in any suitable container, e.g. a glass-capillary (55 x 0.5 mm inner diameter).

20

In Table 1, suitable conditions for the heat treatment of a whole blood sample with a given erythrocyte count, optionally supplemented with organic solvents and/or plasma of blood group AB are shown. These temperature/time conditions are defined by an upper time limit (indicated as value t_{max}) at a given temperature and by a lower time limit (indicated as value t_{min}) at a given temperature. If the heat treatment is carried out for a time period longer than the t_{max} value, gelation occurs. If the heat treatment period is shorter than the t_{min} value, only incomplete disintegration occurs. If other fluids, e.g. organic solvents and/or aqueous fluids, e.g. plasma, are added to the sample before heat treatment, the values of t_{max} and t_{min} may vary as shown in Tables 2-6.

25

30

The gelation of the sample may be determined by an increase in viscosity. The completeness of disintegration may be determined by cell counting, e.g.

- 4 -

in a Neubauer counting chamber, by microscopic inspection for particular components and/or by lack of sediment formation after centrifugation. In this context, it should be noted that about 95% of cellular blood components are represented by erythrocytes. Thus, the cell count in a blood sample is
5 preferably determined by counting the erythrocytes.

By means of the present invention the cell count in the sample is preferably reduced to 0.1% or less and more preferably to 0.01% or less of the original value. For example, when subjecting a sample with 5×10^6 erythrocytes per
10 μl to heat treatment, the cell count is preferably reduced to 5×10^3 cells or less per μl (cf. Example 1), more preferably to 500 cells or less per μl . Most preferably, the sample is free from detectable cells. The absence of particular components may also be determined by light-microscopic observation, e.g. up to 100x magnification, and/or by centrifugation for 10
15 min at up to 3000g, preferably at up to 7400g.

The heat treatment may be carried out when the fluid is kept static, e.g. while the fluid is in a reaction vessel. In a preferred embodiment, however, particularly for automated operations, the heat treatment may be carried out
20 while the fluid is in flow, e.g. while the fluid is passed through a conduit. The heat treatment in a flowing system may be carried out while passing the sample fluid through a heated conduit, e.g. a capillary conduit, preferably with an inner diameter of about 0.1-0.8 mm, for example of about 0.5 mm with a predetermined flow rate, wherein the conduit has a predetermined length in order to achieve the desired residence time within the heated
25 conduit. The heating may be carried out by any suitable means and may comprise e.g. inductive heating such as microwave treatment, for example as described in US 6,605,454, convective heating, resistive heating and/or heating by laser excitation.

30

The biological fluid may be a body fluid such as whole blood, urine, cerebrospinal fluid, saliva, lymph fluid etc. or fluid from a cell culture or any other biological fluid comprising cellular components, particularly fluids

- 5 -

comprising blood cells. More preferably, the biological fluid is whole blood, such as venous, arterial or capillary blood, particularly anticoagulant-treated whole blood, e.g. EDTA-, citrate-, or heparin-treated whole blood. For example, a sample may be taken with an anticoagulant containing blood withdrawal device and directly subjected to further processing as described below.

The sample volume may be varied broadly, e.g. in the range of 1 nl or more, preferably 10 nl or more and up to 1 ml. Thus, the method is suitable for miniaturized applications, e.g. microfluidic devices on chip format, nano LC-MS analysis etc.

The method of the present invention does not require sedimentation and/or precipitation and/or centrifugation steps and/or the addition of chemical lysis and/or disintegration reagents. Thus, the heat treatment is preferably carried out without previous removal and/or lysis of cellular components. The method may be carried out in any suitable device, e.g. a single-use device or a reusable device. Preferably, the method is an automated procedure, which may be carried out in an integrated device, i.e. a device into which the fluid sample is transferred, optionally after mixing, e.g. with a further fluid, without pretreatment, particularly without removal and/or lysis of cellular components. Within the device, the sample is preferably directly subjected to the treatment without prior removal and/or a lysis of cellular components. After treatment, subsequent steps, e.g. an analyte determination may be carried out. Most preferably, the heat treatment is carried out with a substantially native sample, e.g. a sample comprising substantially intact cellular components such as whole blood.

The method of the present invention may include the addition of further fluid to the biological fluid before and/or after processing. The further fluid may be an organic solvent, preferably in an amount of up to 20% (vol/vol), more preferably in an amount of up to 10% (vol/vol) based on the volume of the biological fluid. The organic solvent is preferably selected from water-

- 6 -

miscible solvents such as methanol, ethanol, acetonitrile, dimethylsulfoxide, and combinations thereof. The addition of organic solvents may have an influence on the temperature/time conditions for the heat treatment as shown in Tables 2 and 3.

5

Preferably, the further fluid does not substantially effect lysis of cellular components. More preferably, the further fluid is an aqueous fluid, e.g. an aqueous buffer solution or a further biological fluid, preferably having a ionic strength corresponding to 0.5-1.4% NaCl, more preferably 0.7-1.2% NaCl 10 and most preferably about 0.9% NaCl. Preferably, the aqueous fluid is a biological fluid without cellular components such as plasma. More preferably, the plasma is plasma of the blood group AB. The further aqueous fluid may comprise an organic solvent, e.g. in an amount of up to 20% (vol/vol), preferably up to 10% (vol/vol) based on the volume of the second biological 15 fluid such as methanol, ethanol, acetonitrile, dimethylsulfoxide and/or combinations thereof. The second biological fluid is preferably added in a volume ratio of 5:1 to 1:10 based on the volume of the first biological fluid. Preferably, the second fluid is added before the heat treatment. The addition 20 of the second fluid may influence the suitable temperature/time conditions for the heat treatment step as shown in Tables 4-6. Surprisingly, it was found that addition of AB plasma, optionally with an organic solvent, actually increases the suitable treatment time range at a given temperature.

25

The further fluid may be a standardisation and/or calibrator fluid comprising a predetermined amount of at least one standardisation and/calibrator compound. The addition of standardisation and/or calibrator compounds is particularly suitable if the heat-treated biological fluid is further analysed by means of chromatographic, spectrometric and/or spectroscopic methods. The standardisation and/or calibrator compounds may be analyte analogues 30 which contain stable isotopes such as ²H and/or ¹³C and thus may be detected by mass spectrometry.

The method also may include the addition of a marker/staining compound

- 7 -

for lipids, proteins, peptides, nucleic acids and carbohydrates to the biological fluid before and/or after processing.

A further aspect of the present invention refers to a composition comprising
5 AB plasma, an organic solvent in an amount of up to 20% (vol/vol),
preferably up to 10% (vol/vol) based on the volume of the plasma, such as
methanol, ethanol, acetonitrile and/or dimethylsulfoxide and a predetermined
amount of at least one standardisation and/or calibrator compound. The
compound may be used as a standardisation and/or calibrator fluid,
10 particularly in combination with the heat treatment procedure as described
above.

Still a further aspect of the present invention refers to a processed biological
fluid which is obtainable as described above. The processed fluid represents
15 a novel matrix which is particularly suitable for clinical testing. The
processed fluid is stable at least 1 week, preferably at least 2 weeks at 4°C
and/or at least 1 day, preferably at least 5 days, at 25°C. Thus, the handling
of the processed fluid is much more uncomplicated compared to a non-
treated whole blood sample. The term "stable" particularly means that
20 sedimentation does not occur.

The processed biological fluid comprises substantially quantitatively
disintegrated cellular components such as components from blood cells. The
processed fluid is substantially free from sedimentation, precipitation,
25 denaturation, agglutination and/or gelation products. In a preferred
embodiment, the invention refers to a processed fluid which substantially
(i) is free from particular components on microscopic observation (e.g. 100
x magnification);
(ii) is free from sediment after centrifugation for 10 min. at up to 3000g,
30 preferably at up to 7400 g and/or
(iii) is free from cells as determined in a cell counting chamber.

The processed fluid preferably has a ionic strength corresponding to 0.5-

- 8 -

1.4% NaCl, more preferably 0.7-1.2% NaCl and most preferably a substantially physiological salt concentration. The processed fluid may be free from added disintegration and/or lysis reagents and/or detergents. On the other hand, the processed fluid may also comprise organic solvents 5 and/or added aqueous fluid such as plasma of blood group AB as described above. Most preferably, the processed fluid is processed whole blood.

The present invention also refers to a method of determining an analyte in a biological fluid sample which has been subjected to a heat treatment as 10 described above. The analyte may be any analyte which may be detected in biological fluids, e.g. a biological compound such as a nucleic acid, a polypeptide, peptide, lipid, sugar, hormone, metabolite, etc. On the other hand, the analyte may be a non-biological compound, e.g. a pharmaceutical compound. In a preferred embodiment, the analyte is an 15 immunosuppressive drug, such as cyclosporin, rapamycin or tacrolimus or related compounds.

The analyte determination in the processed fluid may be carried out according to any known method. For example, the analyte determination 20 may be carried out according to chemical, biochemical and/or physicochemical methods and may comprise a hybridization reaction, an immunological reaction, an enzymatic reaction, e.g. a nucleic acid amplification, a chromatographic analysis, a spectrometric analysis, such as a mass-spectrometric or a NMR analysis and/or a spectroscopic analysis. In 25 an especially preferred embodiment, the invention refers to a method of determining an immunosuppressive drug in a whole blood sample, wherein the whole blood is processed by a heat treatment as described above and the immunosuppressive drug is determined in the processed whole blood according to standard methods, e.g. by mass-spectrometric methods.

30

In a further preferred embodiment, the analyte is a clinical-chemical parameter, e.g. a clinical-chemical parameter associated with an inborn metabolic disorder, e.g. phenylketonuria. In this embodiment, the sample is

preferably a capillary blood sample which may be obtained from newborns.

In a still further preferred embodiment, the method is suitable for processing blood samples from non-human animals, preferably mice, guinea pigs and 5 rats. For example, the samples may be taken by automated systems and directly processed as described above. A preferred automated system is the Accu Sampler® from DiLab®.

A device of the present invention may comprise a fluid introduction port, 10 where a sample of a biological fluid may e.g. be injected into the device. The fluid is transported within the device by a fluid transportation element, e.g. a pumping element. Further, the device may comprise a fluid processing conduit which is at least partially heatable. The heatable part of the fluid processing conduit may be an integral part of the device or removably 15 attached to the device. The fluid processing conduit has preferably an inner diameter of about 0.1-0.8 mm. In order to achieve a desired residence time within heatable portion of the conduit a predetermined flow rate of the biological fluid may be adjusted. The heating element may be any suitable heating element, e.g. an element for inductive heating, an element for 20 convective heating, an element for resistive heating and/or an element for heating by laser excitation. For example, the heating element may be a heating coil wrapped around a predetermined part of the fluid processing conduit or a microwave emitter. The control element provides control of the sample processing, particularly the heating of the fluid, e.g. by controlling the 25 heating intensity and/or time and/or the fluid flow rate in the heatable part of the fluid processing conduit.

The device may optionally comprise a cleaning element which is suitable for 30 cleaning the fluid processing conduit or at least a part thereof. For example, the cleaning element is adapted for carrying out a cleaning of the fluid processing conduit or a part thereof after a predetermined number of biological fluid processing cycles. Preferably, the cleaning comprises passing a cleaning fluid through the fluid processing conduit or a part

- 10 -

thereof. The cleaning fluid is capable of removing biological, e.g. proteinaceous residues in the processing conduit. Preferably, the cleaning fluid is an alkaline hypochlorite solution, e.g. an alkaline NaOCl solution. The cleaning may involve flushing of the fluid processing conduit or a part thereof with the cleaning fluid, wherein the cleaning fluid is preferably at an elevated temperature, e.g. at a temperature of $T \geq 60^{\circ}\text{C}$. The cleaning efficacy may be controlled by monitoring the presence of biological materials in the fluid processing conduit or a part thereof after a cleaning procedure. The monitoring preferably comprises a photometric detection of biological material, e.g. proteinaceous material. The detection may be carried out by determining biological materials, which have been solubilised/hydrolysed by the cleaning fluid, preferably in an online detection mode. Biological materials may be determined by a suitable colour reaction, e.g. the OPA reaction wherein O-phthaldialdehyde and N,N-dimethyl-2-mercaptoethyl-ammonium chloride may react with primary amine compounds, e.g. proteins or hydrolysis products, under alkaline conditions (e.g. 0.1 mol/l $\text{Na}_2\text{B}_4\text{O}_7$ pH 9.3) to an 1-alkylthio-2-alkylisoindole, which may be photometrically detected at 340 nm.

Further, the device optionally comprises a sample analysing element. The sample analysing element may be any element which is suitable for analyte detection in a biological sample. Preferably, the sample analysing element comprises a chromatographic element, e.g. an HPLC element, an extraction element, e.g. a Solid Phase Extraction (SPE) element, a spectrometric element, e.g. a mass-spectrometric or NMR element, a spectroscopic element, an enzymatic and/or immunoassay element and/or a hybridization assay element.

Finally, the device may comprise a processor unit which may transfer data to and/or receive data from a remote control unit. The data transfer may occur online, e.g. by wireless transfer such as via GSM/GPRS/3G data transfer. The remote control unit may be adapted to authorise fluid processing for a respective device, e.g. after payment for carrying out a predetermined

- 11 -

number of fluid processing procedures has been received (i.e. pay-per-process).

Further, the present invention is explained in more detail by the following
5 examples.

Example 1: Heat treatment of blood samples (static system)

A glass-capillary (55 mm length x 0.5 mm inner diameter) is filled with about
10 µl of a blood sample (erythrocytes: $5.18 \times 10^6/\mu\text{l}$; hemoglobin: 17.5 g/dl;
hematocrite 50.1%), sealed at one end with plasticine and heated in a
thermostated water-bath at a given temperature for a given time. At the end
of the heating process the glass-capillary is immediately immersed in an ice-
bath (4°C). The plasticine sealing is cut off, the glass-capillary is emptied
15 and the treated blood sample is further investigated for gelation and
completeness of blood cell disintegration. The parameter t_{\max} is defined as
the heating time [sec] at which gelation of the sample occurs minus 1
second. The parameter t_{\min} is defined as the minimal heating time at which
no erythrocytes are detected using a Neubauer counting chamber.

20

Example 2: Erythrocyte count

To 10 µl of whole blood or treated blood 990 µl of Hayemsch-solution (Merck
KGaA, Darmstadt, Germany) are added. The mixture is vortexed and an
25 aliquot is introduced into a Neubauer counting chamber. The erythrocytes
present in 5 defined squares are counted using a microscope and a
magnification of 100.

Calculation:

30

$$\text{Erythrocytes}/\mu\text{l (sample)} = \frac{\text{Number of erythrocytes counted} \times 100}{0.2 \text{ mm}^2 \times 0.1 \text{ mm}}$$

- 12 -

The results are shown in the following Tables 1-6.

| Temperature [°C] | t _{max} [sec] | t _{min} [sec] |
|------------------|------------------------|------------------------|
| 90 | 3 | 3 |
| 85 | 5 | 4 |
| 80 | 9 | 5 |
| 75 | 23 | 9 |
| 70 | 48 | 21 |
| 65 | 242 | 33 |
| 60 | 802 | 349 |

5

10

Table 1: Heat treatment of whole blood (erythrocytes: $5.18 \times 10^6/\mu\text{l}$; hemoglobin: 17.5 g/dl; hematocrite 50.1%).

| Temperature [°C] | t _{max} [sec] | t _{min} [sec] |
|------------------|------------------------|------------------------|
| 80 | 6 | 6 |
| 75 | 13 | 7 |
| 70 | 42 | 11 |
| 65 | 169 | 18 |
| 60 | 646 | 21 |

Table 2: Heat-treatment of whole blood containing 5 vol % of methanol

| Temperature [°C] | t _{max} [sec] | t _{min} [sec] |
|------------------|------------------------|------------------------|
| 80 | 6 | 5 |
| 75 | 10 | 9 |
| 70 | 21 | 10 |
| 65 | 49 | 11 |
| 60 | 184 | 32 |

Table 3: Heat-treatment of whole blood containing 5 vol % of acetonitrile

| Temperature [°C] | t _{max} [sec] | t _{min} [sec] |
|------------------|------------------------|------------------------|
| 80 | 15 | 8 |
| 75 | 31 | 9 |
| 70 | 65 | 41 |
| 65 | 412 | 66 |

Table 4: Heat-treatment of a 1:1 mixture of whole blood and AB-plasma

| Temperature [°C] | t _{max} [sec] | t _{min} [sec] |
|------------------|------------------------|------------------------|
| 80 | 5 | 3 |
| 75 | 13 | 3 |
| 70 | 38 | 3 |
| 65 | 126 | 8 |
| 60 | 693 | 28 |

10 Table 5: Heat-treatment of a 1:1 mixture of whole blood and AB-plasma containing 5 vol % of methanol

15

| Temperature [°C] | t _{max} [sec] | | | t _{min} [sec] | | |
|---------------------|------------------------|-----|----|------------------------|----|----|
| | acetonitrile vol % | | | acetonitrile vol % | | |
| | 2.5 | 5 | 10 | 2.5 | 5 | 10 |
| 80 | 11 | 5 | 3 | 5 | 4 | 1 |
| 75 | 23 | 11 | 4 | 3 | 2 | 1 |
| 70 | 41 | 24 | 5 | 4 | 5 | 1 |
| 65 | 171 | 53 | 17 | 10 | 12 | 1 |
| 60 | 753 | 281 | 35 | 11 | 33 | 2 |

20 25 Table 6: Heat-treatment of a 1:1 mixture of whole blood and AB-plasma containing 2.5, 5 or 10 vol % acetonitrile

Example 3: Heat treatment of a blood sample (Flow system)

30 For the treatment of a blood sample (e.g. 10 µl) using a heated stainless-steel capillary with the dimension of 0.5 mm internal diameter and 300 mm in length, the heating time at a given temperature can be preadjusted via the flow-rate of a given test fluid such as 0.9 vol % NaCl solution.

35 For a temperature of 75°C the minimal capillary retention time t_{min} of 9 sec (cf. Example 1, Table 1) is reached with a flow-rate of 466 µl/min and the maximal capillary retention time t_{max} of 23 sec. (cf. Example 1, Table 1) is reached with a flow-rate of 183 µl/min. Thus, a preferred flow-rate for such a sample size and capillary configuration would be within these boundaries, e.g. amounting to approximately 325 µl/min. This flow-rate is also optimal for

40

- 14 -

electrospray-ionisation in mass spectrometry.

Calculation:

5 Flow rate [$\mu\text{l}/\text{min}$] = Volume Capillary [μl] + Volume Sample [μl] \times 60
 t_{\min} (or t_{\max}) [sec]

Claims

1. A method of processing a biological fluid which comprises cellular components,
5 wherein the fluid is subjected to a heat treatment under conditions
 - (i) to provide substantially quantitative disintegration of said cellular components and
 - (ii) not to cause substantial sedimentation, precipitation, denaturation,
10 agglutination and gelation of fluid components.
2. The method of claim 1 wherein the heat treatment is carried out at a temperature of from 60-90°C, preferably from 60-75°C
- 15 3. The method of claim 1 or 2 wherein the heat treatment is carried out for a time of 5 sec to 1 min.
4. The method of any one of claims 1-3 wherein the heat treatment is carried out while the fluid is static.
5. The method of any one of claims 1-3 wherein the heat treatment is carried out while the fluid is in flow.
- 25 6. The method of any one of claims 1-5 wherein the heat treatment comprises inductive heating, convective heating, resistive heating and/or heating by laser excitation.
7. The method of any one of claims 1-6 wherein the biological fluid is a body fluid or a cell culture fluid, preferably whole blood.
8. The method of any one of claims 1-7 which does not include
 - (i) a sedimentation and/or precipitation step and/or centrifugation step and/or

- 16 -

(ii) an addition of chemical disintegration and/or lysis reagents.

9. The method of any one of claims 1-8 which is carried out as an automated procedure, preferably in an integrated device.

10. The method of any one of claims 1-9 wherein before and/or after processing a further fluid is added.

11. The method of claim 10 wherein the further fluid is an organic solvent in an amount of up to 20 % (vol/vol) based on the volume of the biological fluid, such as methanol, ethanol, acetonitrile and/or dimethylsulfoxide.

12. The method of claim 10 or 11 wherein the further fluid is an aqueous fluid without cellular components optionally comprising an organic solvent in an amount of up to 20 % (vol/vol) based on the volume of the aqueous fluid.

13. The method of claim 12 wherein the further fluid is plasma, particularly plasma of blood group AB.

14. The method of any one of claims 10-13 wherein the further fluid is a standardisation and/or calibrator fluid comprising a predetermined amount of at least one standardization and/or calibrator compound.

15. A processed biological fluid obtainable by the method of any one of claims 1-14.

16. A processed biological fluid comprising substantially quantitatively disintegrated cellular components which is substantially free from sedimentation, precipitation, denaturation, agglutination and gelation products.

17. The processed fluid of claim 15 or 16 which substantially

- (i) is free from particular components on microscopic observation (e.g. 100 x magnification);
- (ii) is free from sediment after centrifugation for 10 min. at up to 3000g, preferably at up to 7400g and/or
- 5 (iii) is free from cells as determined in an cell counting chamber.

18. The processed fluid of any one of claims 15-17 which has a substantially physiological salt concentration.

10 19. The processed fluid of any one of claims 15-18 which is free from added reagents, particularly chemical disintegration and/or lysis reagents and/or detergents.

15 20. The processed fluid of any one of claims 15-19 which is cell-disintegrated blood.

20 21. A method of determining an analyte in a biological fluid sample wherein the biological fluid is processed according to the method of any one of claims 1-14 and the analyte is determined in the processed biological fluid.

22. The method of claim 21 wherein the analyte is selected from biological compounds such as nucleic acids, polypeptides, peptides, lipids, sugars, hormones, metabolites etc. and pharmaceutical compounds.

23. The method of claim 21 or 22 wherein the analyte is an immunosuppressive drug, such as cyclosporin, rapamycin or tacrolimus.

30 24. The method any one of claims 21-23 wherein the determination comprises a hybridization reaction, an immunological reaction, an enzymatic reaction, a chromatographic analysis, a spectrometric analysis and/or spectroscopic analysis.

25. A method of determining an immunosuppressive drug in a whole blood sample wherein the whole blood is processed according to the method of any one of claims 1-14 and the immunosuppressive drug is determined in the processed whole blood.
26. A method of determining a clinical-chemical parameter in a whole blood sample from newborns, wherein the whole blood is processed according to the method of any one of claims 1-14 and the clinical-chemical parameter is determined in the processed whole blood.

10

27. The method of any one of claims 21-26 wherein the sample is processed and determined in an integrated device.
28. A composition comprising a plasma of blood group AB, an organic solvent in an amount of up to 20% (vol/vol) based on the volume of the plasma, such as methanol and/or acetonitrile and a predetermined amount of at least one standardisation and/or calibrator compound.
29. A device for processing a biological fluid which comprises cellular components comprising:
 - (a) a fluid introduction port,
 - (b) a fluid processing conduit, which is at least partially heatable,
 - (c) a heating element for heating a predetermined part of the fluid processing conduit,
 - (d) a fluid transportation element, e.g. a pumping element,
 - (e) a control element for controlling the heating of the fluid under conditions
 - (i) to provide substantially quantitative disintegration of said cellular components and
 - (ii) not to cause substantial sedimentation, precipitation, denaturation, agglutination and gelation of fluid components,
 - (f) optionally a cleaning element and
 - (g) optionally a sample analyzing element.

15

20

25

30

30. The device of claim 29, wherein the fluid processing conduit comprises a heatable conduit, preferably with an inner diameter of about 0.1-0.8 mm.
- 5 31. The device of claim 29 or 30, wherein the heating element is an element for inductive heating, an element for convective heating, an element for resistive heating and/or an element for heating by laser excitation.
- 10 32. The device of any one of claims 29-31, wherein the heatable part of the fluid processing conduit is an integral part of the device.
33. The device of any one of claims 29-31, wherein the heatable part of the fluid processing conduit is removably attached to the device.
- 15 34. The device of any one of claims 29-33, wherein the control element is adapted for controlling the heating intensity and/or the time of heating and/or the fluid flow rate in the heatable part of the fluid processing conduit.
- 20 35. The device of any one of claims 29-34, wherein the cleaning element is adapted for cleaning the fluid processing conduit or a part thereof after a predetermined number of biological fluid processing cycles with a cleaning fluid.
- 25 36. The device of claim 35, wherein the cleaning fluid is an alkaline hypochlorite solution.
37. The device of claim 35 or 36, wherein the cleaning procedure is carried out with a heated cleaning fluid.
38. The device of any one of claims 29-37, wherein the cleaning element is adapted for monitoring the presence of biological materials in the fluid processing conduit or a part thereof after a cleaning procedure.

39. The device of claim 38, wherein the monitoring comprises a photometric detection of biological material.
- 5 40. The device of any one of claims 29-39, wherein the sample analyzing element comprises a chromatographic element, e.g. an HPLC element, an extraction element, e.g. a Solid Phase Extraction (SPE) element, a spectrometric element, e.g. a mass-spectrometric or NMR element, a spectroscopic element, an enzymatic and/or immunoassay element
10 and/or a hybridization assay element.
41. The device of any one of claims 29-40, wherein the device comprises a processor unit which may transfer data to and/or receive data from a remote control unit.
42. The device of claim 41, wherein the remote control unit is adapted to authorise fluid processing in the device.

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2007/005849

A. CLASSIFICATION OF SUBJECT MATTER
INV. G01N33/80 G01N33/96 G01N1/44 G01N33/94

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|---|-----------------------|
| A | <p>MARKUSZEWSKI ET AL: "Human red blood cells targeted metabolome analysis of glycolysis cycle metabolites by capillary electrophoresis using an indirect photometric detection method" JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, NEW YORK, NY, US, vol. 39, no. 3-4, 15 September 2005 (2005-09-15), pages 636-642, XP005039069 ISSN: 0731-7085 page 638, paragraph 2.3</p> <p>-----</p> <p style="text-align: center;">-/-</p> | 1-27, 29-42 |

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

19 September 2007

Date of mailing of the international search report

02/10/2007

Name and mailing address of the ISA/
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Pellegrini, Paolo

INTERNATIONAL SEARCH REPORT

| |
|---|
| International application No PCT/EP2007/005849 |
|---|

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|--|-----------------------|
| A | RENNER S ET AL: "Analysis of metabolites of glucose pathways in human erythrocytes by analytical isotachophoresis" JOURNAL OF CHROMATOGRAPHY, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, VOL. 916, no. 1-2, 4 May 2001 (2001-05-04), pages 247-253, XP004235554 ISSN: 0021-9673 page 248, paragraph 2.2 - paragraph 2.4 ----- | 1-27, 29-42 |
| X | US 4 716 119 A (REHNER HELMUT [DE] ET AL) 29 December 1987 (1987-12-29) column 1, lines 8-19 column 3, lines 65,66 example 1 ----- | 28 |

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2007/005849

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-27,29-42

Method of processing a biological fluid comprising cellular components, wherein the fluid is subjected to heat treatment under conditions to provide quantitative disintegration of said cellular components without causing sedimentation, precipitation, denaturation, agglutination and gelation of fluid components.

2. claim: 28

Composition comprising plasma of blood group AB, an organic solvent up to 20% (vol/vol) and a standardisation or calibrator compound.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/EP2007/005849

| Patent document cited in search report | Publication date | Patent family member(s) | | Publication date |
|--|------------------|-------------------------|------------|------------------|
| US 4716119 | A 29-12-1987 | CA | 1176164 A1 | 16-10-1984 |
| | | DD | 202071 A5 | 24-08-1983 |
| | | DE | 3107060 A1 | 09-09-1982 |
| | | DK | 64482 A | 26-08-1982 |
| | | EP | 0058959 A1 | 01-09-1982 |
| | | IE | 54487 B1 | 25-10-1989 |
| | | JP | 1036588 B | 01-08-1989 |
| | | JP | 1551395 C | 23-03-1990 |
| | | JP | 57157159 A | 28-09-1982 |
| | | NO | 820578 A | 26-08-1982 |